Drugs / MeMuRu-OKA
last change Dec 2006 re-read 2 minutes ago

MeMuRu-OKA

also known as MeMuRu-OKA Vaccine

Vaccine

Developed for
measles · mumps infectious disease · rubella · varicella zoster infection
Investigated by
GlaxoSmithKline

Trials 3 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT00352898 Apr → Nov 2006 measles, mumps infectious disease, rubella, varicella zoster infection GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00353288 Mar → Nov 2006 measles, mumps infectious disease, rubella, varicella zoster infection GlaxoSmithKline Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00351923 Mar → Dec 2006 measles, mumps infectious disease, rubella, varicella zoster infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as MeMuRu-OKA ClinicalTrials.gov intervention name — accepted as the source's own label NCT00351923
2

NCT00352898

NCT00353288

Known as MeMuRu-OKA Vaccine MeMuRu-OKA VaccineNCT00353288
Modality Vaccine “MeMuRu-OKA vaccineNCT00351923